Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo

Figure 5

Effect of ENMD-1198 on growth of colorectal cancer cells in vivo. To determine growth-inhibitory effects of ENMD-1198 in vivo, HUH-7 cells were implanted subcutaneously into mice (n = 10/group) which received either ENMD-1198 (200 mg/kg/day) or diluent when tumors became palpable. A) Treatment with ENMD-1198 led to a significant growth inhibition of xenografted hepatocellular tumors, compared to controls (*P < 0.05). B) Final tumor weights (day 19) in the ENMD-1198 treatment group were significantly lower, compared to excised tumors of the control group (*P < 0.05). Bars: mean ± SEM.

Back to article page